Cynata Therapeutics Limited (ASX:CYP) Insider Paul Wotton Buys 69,767 Shares

Cynata Therapeutics Limited (ASX:CYP) insider Paul Wotton acquired 69,767 shares of the company’s stock in a transaction on Thursday, February 20th. The stock was purchased at an average cost of A$0.30 ($0.19) per share, for a total transaction of A$20,930.10 ($13,331.27).

Cynata Therapeutics Stock Performance

The stock has a market cap of $57.60 million, a P/E ratio of -4.70 and a beta of 0.93.

Cynata Therapeutics Company Profile

Cynata Therapeutics Limited, together with its subsidiaries, develops and commercializes proprietary induced pluripotent stem cell and mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. The company's lead therapeutic product candidate is CYP-001, which has completed Phase I clinical trial for the treatment of graft versus host disease.